

1 Article

## 2 Concise total synthesis of (+)-Zeylenone with 3 antitumor activity and structure-activity relationship 4 of its derivatives

5 Zhonghao Sun<sup>1</sup>, Shuxian Yang<sup>1</sup>, Chengfang Xu<sup>2</sup>, Guoxu Ma<sup>1</sup>, Li Cao<sup>1</sup>, Yu Tian<sup>1</sup>, Jiahao Lin<sup>2\*</sup>,  
6 Xudong Xu<sup>1\*</sup>

7 <sup>1</sup>Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry  
8 of Education; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese  
9 Medicine (Natural Medicine) and Translational Medicine;

10 Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural  
11 Medicine) and Translational Medicine;

12 Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of  
13 Medical Sciences, Beijing, 100193, China

14 <sup>2</sup>China Agricultural University, Beijing, 100193, China

15

16 **Abstract:** (-)-Zeylenone is a promising cytotoxic agent, which is a natural product isolated from  
17 *Uvaria grandiflora Roxb.* Though substantial antitumor mechanism has been researched, little has  
18 focused on its enantiomer (+)-Zeylenone. This article will try to find a gram scale synthesis method  
19 of (+)-Zeylenone and explain the structure-activity relationship of this kind of compound. Total  
20 synthesis of (+)-zeylenone was completed in 13 steps with quinic acid as starting material in 8.8%  
21 overall yield. The highlight of the route was the control of the three carbon's chirality by clever use  
22 of single step dihydroxylation under the direction of the key C-3 chirality. In addition, zeylenone  
23 derivatives were designed and synthesized and their antitumor activity were evaluated against  
24 three human cancer cell lines using the CCK8 assay. Structure-activity relationship suggested  
25 compounds with both two absolute configurations exhibited good activity. Besides, hydroxyls at  
26 C-1/2 position were crucial for the activity and esterification of C-1 hydroxyl with large groups  
27 made the activity disappeared. Hydroxyl at C-3 position was also important as proper ester  
28 substituent could increase the potency.

29

30 **Keywords:** total synthesis; antitumor activity; structure-activity relationship.

### 31 1. Introduction

32 Nowadays despite the growth of different kind of tumor immunotherapy, small molecule  
33 inhibitors still possess significant role in cancer treatment. Natural products have long been  
34 recognized as the richest source of high chemical diversity and its novel scaffold structures can be  
35 used as anticancer agents. It is notable that of all the available anticancer drugs on the market, 70%  
36 have been sourced from natural products or have been derived from plants[1]. Natural products  
37 with excellent anti-tumor activity is worthy of explore and research.

38 (-)-Zeylenone (figure 1) is a natural product isolated from *Uvaria grandiflora Roxb* with potent  
39 inhibition of different cell lines[2]. Its antitumor activity and underlying mechanism were researched  
40 by Cao's group[3-7]. They have demonstrated that (-)-zeylenone strongly suppress chronic  
41 myelogenous leukemia[4], cervical carcinoma[5], prostate cancer[6], gastric cancer[7] both in vitro  
42 and in vivo, and undertook its drug discovery research. So far there existed two total synthesis  
43 methods for (-)-zeylenone. The first enantioselective synthesis was achieved by Ogasawara in

44 1999[8, 9]. They utilized the chiral cyclohexanoid building block to form five naturally occurring  
 45 polyoxygenated cyclohexanes, one of which was (-)-tonkinenin A proved to be identical with  
 46 (-)-zeylenone. In 2006, Liu and co-workers [10, 11] reported a stereoselective synthesis of  
 47 (-)-zeylenone and its enantiomer (+)-zeylenone from shikimic acid. This biosynthetic approach  
 48 oriented starting material facilitated the construction of chiral center resulting in a shorter  
 49 procedure. Besides, Palframan reported a synthesis route from a microbial arene oxidation product,  
 50 and finally found a concise synthesis of representative examples of the (+)-zeylenol and  
 51 (+)-zeylenone families of natural products[12]. The latest method was reported by using D-mannose  
 52 as starting material to synthesize (-)-zeylenol based on mixed aldol condensation reaction[13].


53 So far little has been researched on (+)-zeylenone and its anti-tumor activity. Besides,  
 54 structure-activity relationship of this kind of compounds were not clear. In this article, we will try to  
 55 finish a concise synthesis method of (+)-zeylenone and explain the structure-activity relationship of  
 56 its antitumor activity.

## 57 2. Results And Discussions

### 58 2.1. Total synthesis of (+)-zeylenone

#### 59 2.1.1. Retrosynthesis of (+)-zeylenone


60 The structure of zeylenone contained three chiral center,  $\alpha,\beta$ -unsaturated ketone and multiple  
 61 oxygen substitutions. As we can see the reported methods, the starting material decided the  
 62 efficiency and inspired by the shikimic acid started route, we found D-(-)-quinic acid  
 63 possessed a more likely skeleton. Furthermore, compared the easily prepared synthetic agent QA-4  
 64 [14] and QA-4' [15] from D-(-)-quinic acid with zeylenone (Figure 1), we found three mainly  
 65 different functional groups. And they are benzoylated methylol group at C-7 position, cis vicinal  
 66 diols at C-1/2 position, olefinic bond between C-4/5 position.



67

68 **Figure 1.** structures of zeylenone and synthetic agent QA-4 and QA-4' from D-(-)-quinic acid


69 So we designed a synthetic route from D-(-)-quinic acid via the synthetic agent **QA-4**  
 70 (Scheme 1).



**Scheme 1.** Designed synthetic route from D-(-)-quinic acid to (+)-zeylenone.

### 2.1.2. Synthesis of (+)-zeylenone


**QA-6** was accomplished according to the literature in 44.3 % yield (Scheme 2)[14, 16].



(a) 2,3-Butanedione, trimethylorthoformate, ( $\pm$ )csa; (b)  $\text{NaBH}_4$ , MeOH; (c)  $\text{NaIO}_4$ , Phosphate buffer; (d)  $\text{MsCl}$ ,  $\text{NEt}_3$ ,  $\text{CH}_2\text{Cl}_2$ ; (e) paraformaldehyde, imidazole,  $\text{NaHCO}_3$  (1M), THF; (f)  $\text{BzCl}$ ,  $\text{NEt}_3$ , DMAP

**Scheme 2.** Synthesis of QA-6

The following sharpless dihydroxylation of **QA-6** was tried by potassium osmate without chiral ligands, but yielded the **QA-7** and **QA-7'** with a ratio of 1:0.6 calculated by  $^1\text{H}$ NMR (Scheme 3, Table 1). When treated with the asymmetric catalyst AD-mix- $\alpha$ , single diol isomer **QA-7** was obtained in 65% yield (Table 1).



**Scheme 3.** Synthesis of QA-7

84

Table 1. Asymmetric dihydroxylation of QA-6

catalyst	Ratio
Potassium osmate, NMMO	QA-7:QA2-7' (1:0.6)
AD-mix- $\alpha$	QA-7 (65%), QA-7' (trace)
AD-mix- $\beta$	QA-7' (48%), QA-7 (trace)

85

86

The *cis* vicinal diols **QA-7** were protected by acid-stable cyclic carbonate in consideration of following hydrolysis of six numbered 1,2-diacetal ring. **QA-7** was treated with triphosgene and pyridine in  $\text{CH}_2\text{Cl}_2$  at  $-10^\circ\text{C}$  to give **QA-8** in 93% yield.


88

89

90

91

Hydrolysis of **QA-8** with TFA did not give desired **QA-9**, but produced the unexpected **QA-13** and **QA-14** (Scheme 4). We believed the product **QA-13** is prone to be eliminated. So we treated **QA-13** with catalytic amount DBU refluxed in benzene and obtained **QA-14** in 65% yield [17, 18].



92

93

Scheme 4. Synthesis of QA-14

94

95

96

97

98

99


100

101

102

103

The synthesized **QA-14** in advance made the route a little different from schedule (Scheme 5). The protection of *cis* vicinal diols of **QA-14** with propyl acetal by 2,2-dimethoxypropane gave **QA-15**. **QA-15** was benzoylated and hydrolyzed by benzoyl chloride and 1N hydrochloric acid successively to obtain the target compound (+)-zeylenone. The spectral data (including NMR, MS and IR) of (+)-zeylenone were identical with reference. Besides, the rotation value and sign of the optical rotation  $[\alpha]^{20}_D = +26.1$  ( $c = 0.2$ , MeOH) was in accordance with reference  $[\alpha]^{20}_D = +26$  ( $c = 0.2$ , MeOH). In addition, the Cotton effects in CD spectra (seen in supplementary information) of synthesized compound was opposite to (-)-zeylenone, and the same as (+)-zeylenone. All the data proved the synthesized compound was (+)-zeylenone.



104

105

Scheme 5. Synthesis of (+)-zeylenone

106

107

108

We have attempted to use this method to synthesize (-)-zeylenone via **QA-4'**, but failed at the Baylis-Hillman reaction to **QA-5'**. It was because of the less stable propylacetal protection of vicinal diols.

109

## 2.2. Design and synthesis of zeylenone Derivatives


110

111

112

113


Derivatives with the same absolute configuration of (-)-zeylenone was exhibited in figure 2. (-)-Zeylenone was isolated from the extraction of *Uvaria grandiflora* Roxb in Hainna province. The derivatives zey-1 was synthesized from (-)-zeylenone hydrolysis using ammonia water in methanol. zey-2 and zey-3 were synthesized with the same method as **QA-15** and **QA-16**.



114  
115

**Figure 2.** Derivatives of (-)-zeylenone

116 Besides, in order to investigate the influence of hydroxyls at position C-1/2/3 on the antitumor  
117 activity, we synthesized three series of analogues. QA-15 was utilized as a starting material to  
118 synthesize Series A. The structure of Series A included acetalation of hydroxyls at C-1/2 positions  
119 and different acylation of hydroxyl at C-3 position. Series B was the acetal hydrolyzed products of  
120 corresponding Series A. Series C were acylated from (+)-zeylenone at C-2 position or both C-1/2  
121 positions. The structure of these derivatives were outlined in figure 3.



122  
123

**Figure 3.** Derivatives of (+)-zeylenone

### 124 2.3. Antitumor activity

125 As shown in Table 2, the antitumor activity was measured by IC<sub>50</sub> value against three human  
126 cancer cell lines including melanoma (B16), human hepatocellular carcinoma(HepG2),  
127 euroblastoma SH(SY5Y) using the CCK8 assay. Taxol was used as a standard for comparison.

128

129

**Table 2.** Inhibitory effects of zey derivatives on proliferation of SY5Y, HepG2, B16 cells.

compound	IC <sub>50</sub> ( $\mu$ M)		
	SY5Y	HepG2	B16
(+)-zey	3.411 $\pm$ 0.08	4.001 $\pm$ 0.18	5.326 $\pm$ 0.3
QA-14	8.027 $\pm$ 0.2	18.913 $\pm$ 0.41	21.641 $\pm$ 0.22
QA-15	10.365 $\pm$ 0.15	55.759 $\pm$ 2.9	88.256 $\pm$ 1.55
QA-16	8.027 $\pm$ 0.25	11.913 $\pm$ 0.30	5.641 $\pm$ 0.1
(-)-zey	2.916 $\pm$ 0.05	4.267 $\pm$ 0.17	3.873 $\pm$ 0.26
zey-1	7.961 $\pm$ 0.38	77.180 $\pm$ 0.7	13.295 $\pm$ 0.41
zey-2	8.018 $\pm$ 0.34	40.311 $\pm$ 0.55	12.131 $\pm$ 0.24
zey-3	9.089 $\pm$ 0.2	11.520 $\pm$ 0.31	7.175 $\pm$ 0.05
A1	1.964 $\pm$ 0.19	2.899 $\pm$ 0.04	2.563 $\pm$ 0.11
A2	4.142 $\pm$ 0.25	4.811 $\pm$ 0.1	5.775 $\pm$ 0.51
A3	3.165 $\pm$ 0.08	4.385 $\pm$ 0.09	2.908 $\pm$ 0.22
A4	5.654 $\pm$ 0.13	7.591 $\pm$ 0.18	6.074 $\pm$ 0.21
A5	8.512 $\pm$ 0.02	17.340 $\pm$ 0.5	13.950 $\pm$ 0.5
A6	5.002 $\pm$ 0.13	5.015 $\pm$ 0.52	9.226 $\pm$ 0.19
B1	2.845 $\pm$ 0.92	4.614 $\pm$ 0.48	3.242 $\pm$ 0.24
B2	2.635 $\pm$ 0.36	5.144 $\pm$ 0.5	3.913 $\pm$ 0.43
B3	3.291 $\pm$ 0.31	14.690 $\pm$ 0.22	3.589 $\pm$ 0.74
B4	5.291 $\pm$ 0.64	10.510 $\pm$ 0.45	6.797 $\pm$ 0.04
B5	3.251 $\pm$ 0.52	3.226 $\pm$ 0.15	3.722 $\pm$ 0.1
B6	2.436 $\pm$ 0.6	5.968 $\pm$ 0.21	2.812 $\pm$ 0.6
C1	4.018 $\pm$ 0.50	10.300 $\pm$ 0.74	2.131 $\pm$ 0.58
C2	22.021 $\pm$ 0.6	8.226 $\pm$ 0.51	10.023 $\pm$ 0.27
C3	6.225 $\pm$ 0.2	8.824 $\pm$ 0.11	16.253 $\pm$ 0.06
C4	3.089 $\pm$ 0.60	11.52 $\pm$ 0.18	4.175 $\pm$ 0.17
C5	9.275 $\pm$ 0.19	5.664 $\pm$ 0.08	9.478 $\pm$ 0.04
C6	20.493 $\pm$ 0.06	9.015 $\pm$ 0.18	>100
C7	35.361 $\pm$ 0.8	29.356 $\pm$ 0.5	44.278 $\pm$ 3.5
C8	>100	60.997 $\pm$ 2.11	>100
taxol	2.88 $\pm$ 0.24	5.42 $\pm$ 0.38	3.56 $\pm$ 0.35

#### 130 2.4. Structure-activity relationship

131 Evaluation of (+)-zeylenone (3.411, 4.001, 53.26) and enantiomer (-)-zeylenone (2.916, 4.267,  
 132 3.873) showed similar IC<sub>50</sub> value, which indicated both the two absolute configurations possessed  
 133 potent activity. The relationship between absolute configuration and activity was proved by  
 134 another pair of enantiomers **QA-16** and **zey-3**, which showed almost the same toxicity against three  
 135 cell lines. Besides debenzoylated compounds at C-3 position (**QA-14**, **QA-15**, **zey-1**, **zey-2**) showed  
 136 same declining trend of activity. But they were slightly more sensitive to SY5Y. The initial  
 137 structure-activity relationship suggested both two absolute configurations exhibited good activity,  
 138 and the debenzoylation at C-3 position could reduce the efficiency.

139 Generally, series A and B showed relatively potent activity. Compared series A with **QA-15**  
 140 and series B with **QA-14**, we can conclude that acylation of hydroxyl at C-3 position is important to  
 141 the activity. **A1** showed the highest IC<sub>50</sub> value to three cell lines, and its acetalation counterpart **B1**  
 142 also exhibited excellent activity, which suggested that the 4-fluorobenzoylation of hydroxyl at C-3  
 143 position could definitely improve the antitumor activity. The *para*-methyl and *para*-methoxyl  
 144 substituent of C-3 benzoylation could either improve or maintain the activity. But **B3** showed  
 145 exceptionally low activity against hepg2. Cyclohexane esters **A4** and **B4** possessed a less than 10  
 146 micromole IC<sub>50</sub> value. The activity of **A5** and **A6** were improved compared with **QA-16**, meanwhile  
 147 **B5** and **B6** have a higher IC<sub>50</sub> value than (-)-zeylenone, which indicated that increase of carbon chain

148 between C-3 acyl and aromatic ring is beneficial to the increase of activity, but the correlation  
149 between carbon chain length and activity is not obvious.

150 Overall, esterification of hydroxyls at C-1/2 position decreased the activity, especially at C-1.  
151 Compared the mono esterification compounds (C1, C3, C5, C7) with the corresponding double  
152 esterification compounds (C2, C4, C6, C8), we could find an obvious decrease of activity. The  
153 cinnamic acid esterified C8 almost showed no antitumor efficacy. All this information suggested  
154 hydroxyls at C-1/2 position were crucial for the activity and esterification of large groups at C-1  
155 hydroxyl made the activity disappeared.

### 156 3. Experiment Section

#### 157 3.1 General

158 The products were purified by column chromatography on silica gel (200~300 mesh, Qingdao  
159 Marine Chemical plant, Qingdao, People's Republic of China). Precoated silica gel GF254 plates (Zhi  
160 Fu Huang Wu Pilot Plant of Silica Gel Development, Yantai, China) were needed for TLC. High  
161 resolution mass spectra (HR-ESI-MS) was conducted with ThermoFisher Scientific LTQ-Orbitrap XL  
162 spectrometer. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were acquired with a Bruker AV III 600 NMR  
163 spectrometer (chemical shift values are shown as  $\delta$  values with TMS as the internal standard).  
164 Abbreviations are as follows: s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m  
165 (multiplet), bs (broad singlet). Chemical shifts ( $\delta$ ) are given in ppm relative to solvent residual peak  
166 (CDCl<sub>3</sub>,  $\delta$  = 7.26 ppm, CD<sub>3</sub>OD,  $\delta$  = 3.3 ppm) as external standard. All the in vitro tests were carried  
167 out in accordance with guidelines evaluated and approved by the Institute of Medicinal Plant  
168 Development (IMPLAD).

#### 169 3.2 Synthesis and Characterization Data

##### 170 3.2.1 QA-4

171 QA-4 was synthesis according to the ref[14].

172 <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  6.87 (s, 1H), 6.00 (s, 1H), 4.51 (s, 1H), 4.06 (s, 1H), 3.32 (s, 3H), 3.27  
173 (s, 3H), 2.74 (d,  $J$  = 14.8 Hz, 1H), 2.49–2.47 (m, 1H), 1.34 (s, 3H), 1.33 (s, 3H). <sup>13</sup>C NMR (150 MHz,  
174 CDCl<sub>3</sub>)  $\delta$  196.90 (s), 148.59 (s), 130.10 (s), 100.79 (s), 99.71 (s), 69.23 (s), 68.08 (s), 48.24 (s), 48.16 (s),  
175 42.02 (s), 17.73 (s), 17.68 (s). HRMS (ESI):  $m/z$  calcd. C<sub>12</sub>H<sub>18</sub>NaO<sub>5</sub> [M + Na]<sup>+</sup>: 265.1052, found 265.1175;  
176 data are in agreement with reported values.

##### 177 3.2.2 QA-5

178 QA-4 (2.8 g, 12 mmol) was dissolved in 50 ml THF, 50 ml sodium bicarbonate solution (1M),  
179 imidazole (0.9 g, 13.2 mmol) and polyformaldehyde (720 mg, 24 mmol) were added successively..  
180 After stirred for 2 h at RT, the mixture was extracted with ethyl acetate, washed with water, dried  
181 (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Crude product was purified by silica gel  
182 column chromatography (petroleum ether: ethyl acetate, 1:1) to give QA-5 (2.78g, 85%). White  
183 powder; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  6.83 (d,  $J$  = 1.4 Hz, 1H), 4.51 – 4.50 (m, 1H), 4.30 – 4.28 (m, 1H),  
184 4.20 – 4.18 (m, 1H), 4.01 (ddd,  $J$  = 13.8, 9.0, 4.8, Hz, 1H), 3.30 (s, 3H), 3.24 (s, 3H), 2.74 (ddd,  $J$  = 16.4,  
185 4.8, 2.0 Hz, 1H), 2.53 – 2.48 (m, 1H), 2.40 (bs, 1H, OH), 1.34 (s, 3H), 1.31 (s, 3H); <sup>13</sup>C NMR (150 MHz,  
186 CDCl<sub>3</sub>)  $\delta$  197.39 (s), 144.50 (s), 139.28 (s), 100.94 (s), 99.90 (s), 69.25 (s), 68.18 (s), 60.83 (s), 48.38 (s),  
187 48.30 (s), 42.30 (s), 17.87 (s), 17.82 (s). HRMS (ESI):  $m/z$  calcd. C<sub>13</sub>H<sub>20</sub>NaO<sub>6</sub> [M + Na]<sup>+</sup>: 295.1158, found  
188 295.1175; data are in agreement with reported values[16].

##### 189 3.2.3 QA-6



190 QA-5 (2.8 g, 12 mmol) was dissolved in 30 ml DCM, then triethylamine (1.3 ml, 24 mmol),  
191 DMAP (150 mg, 1.2 mmol), benzoyl chloride (2.1 ml, 18 mmol) were added successively. After  
192 stirred for 2 h at RT, the reaction was quenched with saturated sodium bicarbonate solution, and  
193 extraction with DCM, washed with water, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated under reduced  
194 pressure. Crude product was purified by silica gel column chromatography (petroleum ether: ethyl  
195 acetate, 4:1) to give QA-6 (4.5g, 98%). White powder;  $^1\text{H}$ NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.09 (d,  $J$  = 6.3 Hz,  
196 2H), 7.61 (s, 1H), 7.49 (d,  $J$  = 6.3 Hz, 2H), 6.93 (s, 1H), 5.09 (d,  $J$  = 13.3 Hz, 1H), 5.05 (d,  $J$  = 13.3 Hz, 1H),  
197 4.58 (d,  $J$  = 5.6 Hz, 1H), 4.09 (s, 1H), 3.34 (s, 3H), 3.32 (s, 3H), 2.85 (dd,  $J$  = 15.7, 4.2 Hz, 1H), 2.59 (t,  $J$  =  
198 14.5 Hz, 1H), 1.39 (s, 3H), 1.36 (s, 3H);  $^{13}\text{C}$ NMR (150 MHz,  $\text{CDCl}_3$ )  $\delta$  195.17 (s), 165.99 (s), 144.80 (s),  
199 135.45 (s), 133.28 (s), 129.79 (s), 128.48 (s), 100.85 (s), 99.75 (s), 69.20 (s), 67.92 (s), 60.77 (s), 48.35 (s),  
200 48.21 (s), 42.09 (s), 17.75 (s), 17.69 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{20}\text{H}_{24}\text{NaO}_7$  [ $\text{M} + \text{Na}$ ] $^+$ : 399.1420, found  
201 399.1440.

### 202 3.2.4 QA-7

203 QA-6 (3.76 g, 10 mmol) was dissolved in 50 ml THF and 10 ml of water. AD-mix-a (1g, equiv:  
204 0.1g/mmol) was added while vigorously stirring. After stirred for 7 h at RT, the reaction was  
205 quenched with saturated sodium thiosulfate solution, and extraction with ethyl acetate, washed  
206 with saturated sodium chloride, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated under reduced pressure. Crude  
207 product was purified by silica gel column chromatography (petroleum ether: ethyl acetate, 1:1) to  
208 give QA-7 (2.66g, 65%). White powder;  $M_p$  190-192  $^\circ\text{C}$ ;  $[\alpha]_D^{20}$  = +32 ( $c$  = 0.6,  $\text{CHCl}_3$ ); IR (KBr)  $\text{cm}^{-1}$   
209 3314, 2933, 1715, 1267, 978;  $^1\text{H}$ NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.99 – 7.97 (m, 2H), 7.62 (m, 1H), 7.47 (m, 2H),  
210 5.00 – 4.99 (m, 1H), 4.05 – 4.00 (m, 1H), 3.94 – 3.90 (m, 1H), 3.85 (d,  $J$  = 10.4 Hz, 1H), 3.51 – 3.48 (m, 1H),  
211 3.35 (s, 3H), 3.32 (s, 3H), 2.96 (dd,  $J$  = 18.7, 5.9 Hz, 1H), 2.74 (dd,  $J$  = 18.6, 11.9 Hz, 1H), 1.41 (s, 3H), 1.35  
212 (s, 3H);  $^{13}\text{C}$ NMR (150 MHz,  $\text{CDCl}_3$ )  $\delta$  196.13 (s), 164.92 (s), 133.35 (s), 129.78 (s), 129.42 (s), 128.48 (s),  
213 99.61 (s), 99.43 (s), 82.02 (s), 79.40 (s), 71.97 (s), 60.54 (s), 48.49 (s), 48.43 (s), 41.44 (s), 17.52 (s), 17.45 (s);  
214 HRMS (ESI):  $m/z$  calcd.  $\text{C}_{20}\text{H}_{26}\text{NaO}_9$  [ $\text{M} + \text{Na}$ ] $^+$ : 433.1475, found 433.1499

### 215 3.2.5 QA-8

216 QA-7 (2.0 g, 5 mmol) was dissolved in 20 ml DCM at  $0^\circ\text{C}$  under  $\text{N}_2$ . Triphosgene (2.2 g,  
217 7.5 mmol) dissolved in 10 ml DCM was added dropwise via syringe over 10 min, followed by  
218 pyridine (0.4 mL, 5 mmol). After stirred for 1 h at RT, the reaction was quenched with saturated  
219 sodium bicarbonate solution, and extraction with DCM, washed with saturated sodium chloride,  
220 dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated under reduced pressure. QA-8 (2.0g, 93%) was obtained by silica  
221 gel column chromatography (petroleum ether: ethyl acetate, 3:1). White powder;  $M_p$  188-189  $^\circ\text{C}$ ;  
222  $[\alpha]_D^{20}$  = -18 ( $c$  = 0.2,  $\text{CHCl}_3$ ); IR (KBr)  $\text{cm}^{-1}$  2963, 1720, 1286, 978, 783;  $^1\text{H}$ NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$   
223 8.01 – 8.00 (m, 2H), 7.65 (m, 1H), 7.49 (m, 2H), 4.91 (d,  $J$  = 8.4 Hz, 1H), 4.67 (d,  $J$  = 12.3 Hz, 1H), 4.60 (d,  
224  $J$  = 12.2 Hz, 1H), 4.08 (td,  $J$  = 11.2, 6.6 Hz, 1H), 3.94 (dd,  $J$  = 11.1, 8.5 Hz, 1H), 3.34 (s, 3H), 3.28 (s, 3H),  
225 3.02 (dd,  $J$  = 18.6, 6.5 Hz, 1H), 2.78 (dd,  $J$  = 18.6, 11.3 Hz, 1H), 1.38 (s, 3H), 1.34 (s, 3H);  $^{13}\text{C}$ NMR (150  
226 MHz,  $\text{CDCl}_3$ )  $\delta$  196.85 (s), 168.61 (s), 167.52 (s), 134.11 (s), 129.88 (s), 128.78 (s), 128.17 (s), 99.57 (s),  
227 99.44 (s), 83.02 (s), 78.33 (s), 72.09 (s), 64.47 (s), 60.48 (s), 48.47 (s), 41.25 (s), 17.50 (s), 17.43 (s); HRMS  
228 (ESI):  $m/z$  calcd.  $\text{C}_{21}\text{H}_{24}\text{NaO}_{10}$  [ $\text{M} + \text{Na}$ ] $^+$ : 459.1267, found 459.1292.

### 229 3.2.6 QA-13 and QA-14



230 QA-8 (2 g, 5 mmol) was dissolved in 20 ml DCM, and 3 ml TFA:H<sub>2</sub>O (6:1) mixture was added.  
231 After stirred for 2 h at RT, the reaction was quenched with saturated sodium bicarbonate solution,  
232 and extraction with DCM, washed with saturated sodium chloride, dried (Na<sub>2</sub>SO<sub>4</sub>), and  
233 concentrated under reduced pressure. QA-13 (858 mg, 58%) was obtained by silica gel column  
234 chromatography (DCM: MeOH, 20:1). QA-14 (450 mg, 24%) was obtained by silica gel column  
235 chromatography (DCM: MeOH, 10:1)

236 QA-13 (800 mg, 2.7 mmol) was dispersed in 10 ml benzene in a sealed tube. DBU (228 μL, 1.5  
237 mmol) was added and the reaction was refluxed for 12 hours at 100 °C. The reaction was  
238 concentrated under reduced pressure. QA-14 (480 mg, 65%) was obtained by silica gel column  
239 chromatography (DCM: MeOH, 10:1)

240 QA-13: Mp 178-179 °C, white solid;  $[\alpha]_D^{20} = -33.8$  (c = 0.2, MeOH); IR (KBr) cm<sup>-1</sup> 3312, 2975,  
241 1714, 1265, 981, 775; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.94 (d, J = 7.6 Hz, 2H), 7.54 (s, 1H), 7.40 (t, J = 7.6  
242 Hz, 2H), 4.93 (s, 1H), 4.70 (d, J = 12.3 Hz, 1H), 4.64 (d, J = 12.6 Hz, 1H), 4.46 (s, 1H), 4.25 (s, 1H), 3.98 (s,  
243 1H), 3.13 – 3.10 (m, 1H), 2.77 – 2.74 (m, 1H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 200.24 (s), 165.92 (s), 133.96  
244 (s), 129.82 (s), 128.73 (s), 128.39 (s), 82.27 (s), 82.02 (s), 68.64 (s), 67.92 (s), 64.38 (s), 41.51 (s); HRMS  
245 (ESI): m/z calcd. C<sub>14</sub>H<sub>16</sub>NaO<sub>7</sub> [M + Na]<sup>+</sup>: 319.0794, found 319.0803

246 QA-14: Mp 145-146 °C; white solid;  $[\alpha]_D^{20} = 21.9$  (c = 0.2, CHCl<sub>3</sub>); IR (KBr) cm<sup>-1</sup> 3309, 2955, 1720,  
247 1286, 978, 783; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.98 (d, J = 7.6 Hz, 2H), 7.57 (d, J = 7.3 Hz, 1H), 7.43 (t, J =  
248 7.6 Hz, 2H), 6.92 (dd, J = 10.2, 2.5 Hz, 1H), 6.17 (d, J = 10.2 Hz, 1H), 4.79 (d, J = 11.3 Hz, 1H), 4.70 (s,  
249 1H), 4.59 (d, J = 11.3 Hz, 1H), 3.97 (d, J = 4.7 Hz, 1H), 3.63 (s, 1H), 3.48 – 3.42 (m, 1H); <sup>13</sup>C NMR (150  
250 MHz, CDCl<sub>3</sub>) δ 195.33 (s), 166.94 (s), 147.88 (s), 133.68 (s), 129.91 (s), 129.01 (s), 128.56 (s), 126.96 (s),  
251 74.08 (s), 68.00 (s), 64.12 (s); HRMS (ESI): m/z calcd. C<sub>14</sub>H<sub>14</sub>NaO<sub>6</sub> [M + Na]<sup>+</sup>: 301.0688, found 301.0703

### 252 3.2.7. QA-15

253 QA-14 (900 mg, 3.2 mmol) was dissolved in 10 ml acetone, *p*-toluene sulfonic acid  
254 monohydrate (55 mg, 0.3 mmol), 2,2-dimethoxypropane (620 mL) was added successively. After  
255 stirred at room temperature for 2 hours, the reaction was concentrated. Crude product was purified  
256 by silica gel column chromatography (petroleum ether: ethyl acetate, 3:1) to give QA-15 (890 mg,  
257 88%). white solid; M p 154-155 °C;  $[\alpha]_D^{20} = -14.5$  (c = 0.2, CHCl<sub>3</sub>); IR (KBr) cm<sup>-1</sup> 3311, 2975, 1698, 1640,  
258 1186, 973, 778; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.01 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.3 Hz, 1H), 7.47 (t, J =  
259 7.5 Hz, 2H), 7.00 (dd, J = 10.0, 4.6 Hz, 1H), 6.26 (d, J = 10.2 Hz, 1H), 4.71 (d, J = 11.6 Hz, 2H), 4.58 (d, J =  
260 11.5 Hz, 1H), 4.54 (s, 1H), 2.68 (s, 1H), 1.47 (s, 4H), 1.39 (s, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 195.95  
261 (s), 166.11 (s), 145.71 (s), 133.69 (s), 129.73 (s), 128.69 (s), 128.63 (s), 109.61 (s), 80.36 (s), 79.87 (s), 64.67  
262 (s), 64.54 (s), 27.42 (s), 26.34 (s); HRMS (ESI): m/z calcd. C<sub>17</sub>H<sub>18</sub>NaO<sub>6</sub> [M + Na]<sup>+</sup>: 341.1001, found  
263 341.1015.

### 264 3.2.8. QA-16

265 QA-15 (850 mg, 2.7 mmol) was dissolved in 5 ml DCM, then triethylamine (0.6 ml, 4 mmol),  
266 DMAP (25 mg, 0.2 mmol), benzoyl chloride (360 μL, 3mmol) were added successively. After  
267 stirred for 2 h at RT, the reaction was quenched with saturated sodium bicarbonate solution, and  
268 extraction with DCM, washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced  
269 pressure. Crude product was purified by silica gel column chromatography (petroleum ether: ethyl  
270 acetate, 4:1) to give QA-16 (1.0g, 95%). White powder; M p 147-148 °C;  $[\alpha]_D^{20} = +20.4$  (c = 0.2, CHCl<sub>3</sub>);  
271 IR (KBr) cm<sup>-1</sup> 2936, 1728, 1671, 1296, 972, 785; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.97 (d, J = 7.9 Hz, 2H),

272 7.88 (d,  $J = 7.9$  Hz, 2H), 7.53 (ddd,  $J = 10.5, 9.9, 4.0$  Hz, 2H), 7.39 (dd,  $J = 11.0, 4.3$  Hz, 2H), 7.31 (d,  $J = 7.5$   
273 Hz, 2H), 7.09 (ddd,  $J = 10.0, 4.8, 1.7$  Hz, 1H), 6.41 (d,  $J = 10.2$  Hz, 1H), 6.00 (d,  $J = 4.8$  Hz, 1H), 4.72 (m,  
274 2H), 4.62 (d,  $J = 12.0$  Hz, 1H), 1.51 (s, 3H), 1.44 (s, 3H);  $^{13}\text{C}$ NMR (150 MHz,  $\text{CDCl}_3$ )  $\delta$  195.61 (s), 165.67  
275 (s), 165.25 (s), 141.49 (s), 133.68 (s), 133.41 (s), 130.68 (s), 129.77 (s), 129.72 (s), 129.14 (s), 128.50 (s),  
276 128.48 (s), 110.07 (s), 80.02 (s), 77.70(s), 65.99 (s), 63.91 (s), 27.41 (s), 26.42 (s); HRMS (ESI):  $m/z$  calcd.  
277  $\text{C}_{24}\text{H}_{22}\text{NaO}_7$   $[\text{M} + \text{Na}]^+$ : 445.1263, found 445.1291

### 278 3.2.8. (+)-zeylenone

279 To 5 ml methanol of QA-16 (1.0 g, 2.3 mmol) solution was added 2 ml 1N dilute hydrochloric  
280 acid. After stirred for 2 h at RT, the reaction was concentrated under reduced pressure as crude  
281 products. (+)-zeylenone (792 mg, 90%) was obtained by silica gel column chromatography  
282 purification (petroleum ether: ethyl acetate, 2:1). white powder; M p 147-148°C;  $[\alpha]^{20}_D = +26.1$  ( $c =$   
283 0.2, MeOH); IR (KBr)  $\text{cm}^{-1}$  3328, 2933, 1720, 1685, 978, 783;  $^1\text{H}$ NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.03 – 8.01 (m,  
284 2H), 7.94 – 7.93 (m, 2H), 7.56 (dt,  $J = 10.2, 7.5$  Hz, 2H), 7.42 (dt,  $J = 16.0, 7.9$  Hz, 4H), 6.97 (ddd,  $J = 10.2,$   
285 4.1, 1.2 Hz, 1H), 6.35 (d,  $J = 10.2$  Hz, 1H), 5.96 (t,  $J = 3.7$  Hz, 1H), 4.85 (d,  $J = 11.5$  Hz, 1H), 4.60 (d,  $J =$   
286 11.5 Hz, 1H), 4.38 (s, 1H), 4.09 (s, OH), 3.20 (d,  $J = 2.4$  Hz, OH);  $^{13}\text{C}$ NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  196.42  
287 (s), 166.37 (s), 165.48 (s), 142.85 (s), 133.98 (s), 133.63 (s), 129.97 (s), 129.90 (s), 128.84 (s), 128.73 (s),  
288 128.63 (s), 71.80 (s), 69.31 (s), 65.61 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{21}\text{H}_{18}\text{NaO}_7$   $[\text{M} + \text{Na}]^+$ : 405.0950, found  
289 405.0972. CD spectrum seen in **Appendix** are in agreement with reported values[10].

### 290 3.2.9. (-)-zeylenone

291 Isolated from *Uvaria grandiflora* Roxb in Hainan Province. M p 147-148°C, white solid;  $[\alpha]^{20}_D =$   
292  $-26.1$  ( $c = 0.2, \text{MeOH}$ ); IR (KBr)  $\text{cm}^{-1}$  3324, 2968, 1721, 1670, 975, 787;  $^1\text{H}$ NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.08  
293 – 8.00 (m, 2H), 8.00 – 7.88 (m, 2H), 7.65 – 7.52 (m, 2H), 7.42 (dt,  $J = 15.9, 7.9$  Hz, 4H), 6.97 (ddd,  $J = 10.2,$   
294 4.1, 1.3 Hz, 1H), 6.34 (d,  $J = 10.2$  Hz, 1H), 5.96 (t,  $J = 3.6$  Hz, 1H), 4.85 (d,  $J = 11.5$  Hz, 1H), 4.60 (d,  $J =$   
295 11.5 Hz, 1H), 4.38 (s, 1H), 4.10 (s, OH), 3.20 (d,  $J = 2.4$  Hz, OH);  $^{13}\text{C}$ NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  196.42  
296 (s), 166.37 (s), 165.49 (s), 142.85 (s), 133.97 (s), 133.63 (s), 129.97 (s), 129.90 (s), 129.24 (s), 128.88 (s),  
297 128.84 (s), 128.73 (s), 128.63 (s), 71.80 (s), 69.32 (s), 65.60 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{21}\text{H}_{18}\text{NaO}_7$   $[\text{M} +$   
298  $\text{Na}]^+$ : 405.0950, found 405.0969. CD spectrum seen in **Appendix** are in agreement with reported  
299 values[11].

### 300 3.2.9. zey-1

301 The isolated (-)-zeylenone (1 g, 3.3 mmol) was dissolved in 20 ml methanol. 10 ml ammonia  
302 water was added, and the reaction was stirred for 4 hours at 80°C. The reaction was concentrated  
303 under reduced pressure, zey-1 (410 mg, 45%) was obtained by silica gel column chromatography  
304 (DCM: MeOH, 10:1); white solid; M p 145-146 °C;  $[\alpha]^{20}_D = -22$  ( $c = 0.2, \text{CHCl}_3$ ); IR (KBr)  $\text{cm}^{-1}$  3308,  
305 2954, 1725, 977, 785;  $^1\text{H}$ NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.97 (d,  $J = 7.5$  Hz, 1H), 7.57 (t,  $J = 7.3$  Hz, 1H), 7.44  
306 (t,  $J = 7.5$  Hz, 1H), 6.92 (dd,  $J = 10.2, 2.5$  Hz, 1H), 6.16 (d,  $J = 10.2$  Hz, 1H), 4.79 (d,  $J = 10.8$  Hz, 1H),  
307 4.69 (s, 1H), 4.58 (d,  $J = 11.3$  Hz, 1H), 3.96 (d,  $J = 4.7$  Hz, 1H), 3.62 (s, 1H), 3.47 (s, 1H);  $^{13}\text{C}$ NMR (150  
308 Hz,  $\text{CDCl}_3$ )  $\delta$  195.47 (s), 167.08 (s), 148.02 (s), 133.82 (s), 130.05 (s), 129.15 (s), 128.70 (s), 127.10 (s),  
309 76.43 (s), 74.22 (s), 68.14 (s), 64.26 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{14}\text{H}_{14}\text{NaO}_6$   $[\text{M} + \text{Na}]^+$ : 301.0688, found  
310 301.0719.

### 311 3.2.10. zey-2

312 Zey-2 was synthesized by the same method as QA-15. white solid; M p 154-155°C;  $[\alpha]^{20}_D = 14.5$   
313 (c = 0.2, CHCl<sub>3</sub>); IR (KBr) cm<sup>-1</sup> 3308, 2963, 1720, 1655, 1186, 978, 783; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.00  
314 (dd, J = 23.4, 7.7 Hz, 2H), 7.59 (t, J = 7.3 Hz, 1H), 7.45 (t, J = 7.5 Hz, 2H), 6.98 (dd, J = 10.0, 4.6 Hz,  
315 1H), 6.23 (d, J = 10.2 Hz, 1H), 4.68 (d, J = 11.6 Hz, 2H), 4.56 (d, J = 11.2 Hz, 1H), 4.51 (s, 1H), 1.45 (s,  
316 3H), 1.36 (s, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 196.10 (s), 166.25 (s), 145.86 (s), 133.84 (s), 129.87 (s),  
317 128.83 (s), 128.77 (s), 109.76 (s), 80.51 (s), 80.02 (s), 64.82 (s), 64.69 (s), 27.57 (s), 26.49 (s); HRMS (ESI):  
318 m/z calcd. C<sub>17</sub>H<sub>18</sub>NaO<sub>6</sub> [M + Na]<sup>+</sup>: 301.1001, found 341.1007.

### 319 3.2.10. zey-3

320 Zey-3 was synthesized by the same method as QA-16. white solid; M p 147-148°C;  $[\alpha]^{20}_D =$   
321 -20.4 (c = 0.2, CHCl<sub>3</sub>); IR (KBr) cm<sup>-1</sup> 2933, 1720, 1665, 1286, 978, 783; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.94  
322 (d, J = 7.9 Hz, 2H), 7.84 (d, J = 7.9 Hz, 2H), 7.51 (dd, J = 6.7, 5.5 Hz, 2H), 7.35 (m, 2H), 7.28 (d, J = 7.5 Hz,  
323 2H), 7.06 (m, 1H), 6.38 (d, J = 10.2 Hz, 1H), 5.97 (d, J = 4.7 Hz, 1H), 4.70 (d, J = 11.6 Hz, 1H), 4.68 (s, 1H),  
324 4.62 (d, J = 11.7 Hz, 1H), 1.48 (s, 3H), 1.40 (s, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 195.61 (s), 165.67 (s),  
325 165.25 (s), 141.49 (s), 133.68 (s), 133.41 (s), 130.68 (s), 129.77 (s), 129.72 (s), 129.14 (s), 128.50 (s), 128.48  
326 (s), 110.07 (s), 80.02 (s), 77.70 (s), 65.99 (s), 63.91 (s), 27.41 (s), 26.42 (s); HRMS (ESI): m/z calcd.  
327 C<sub>24</sub>H<sub>22</sub>NaO<sub>7</sub> [M + Na]<sup>+</sup>: 445.1263, found 445.1266.

### 328 3.2.10. synthesis of series A

329 Series A compounds were synthesized from Zey-2.

330 (1R, 2R, 3S)-1,2-propylacetal-3-*p*-fluorobenzoyl-zeilynone(A1): Zey-2 (50mg, 0.15mmol),  
331 DMAP (2.0mg, 0.015mmol) DCC (61mg, 0.3mmol) were dissolved in 1ml DCM, and  
332 *p*-fluorobenzoic acid (280mg, 0.2mmol) was added to the reaction. After the reaction was stirred for  
333 12 h at room temperature, the solvent was dried and added 1 mL ether. The mixture was filtered  
334 and concentrated to get the crude product. Crude product was purified by silica gel column  
335 chromatography (petroleum ether: ethyl acetate, 4:1) to give A1 (60 mg, 90%). White powder;  $[\alpha]^{20}_D$   
336 =13.1 (c = 0.3, CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, 298K, CDCl<sub>3</sub>): δ (ppm)= 7.93 (dd, J = 8.2, 1.2 Hz, 2H, Ar-H),  
337 7.88-7.82 (m, 2H, Ar-H), 7.56-7.50 (m, 1H, Ar-H), 7.37 (t, J = 7.8 Hz, 2H, Ar-H), 7.04 (ddd, J = 10.2, 4.9,  
338 1.8 Hz, 1H, H-4), 6.98-6.88 (m, 2H, Ar-H), 6.39 (d, J = 10.2 Hz, 1H, H-5), 5.94 (dd, J = 4.9, 1.2 Hz, 1H,  
339 H-3), 4.69-4.62 (m, 3H, H-2, H-7a, 7b), 1.48 (s, 3H, Me), 1.41 (s, 3H, Me). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>):  
340 δ (ppm)= 195.7 (s, C-1), 166.8 (d, J<sub>C-F</sub> = 253.9 Hz, C-F), 166.4 (s, C=O), 164.6 (s, C=O), 141.5 (s, C-4),  
341 133.7 (s, Ar-C), 132.6 (s, Ar-C), 132.6 (s, Ar-C), 130.9 (s, C-5), 129.8 (s, 2 × Ar-C), 129.2 (s, Ar-C), 128.7  
342 (s, 2 × Ar-C), 124.9 (s, Ar-C), 115.9 (s, Ar-C), 115.8 (s, Ar-C), 110.2 (s, CO<sub>2</sub>(Me)<sub>2</sub>), 80.1 (s, C-2), 77.8 (s,  
343 C-1), 66.3 (s, C-3), 64.1 (s, C-7), 27.6 (s, Me), 26.6 (s, Me); HRMS (ESI): m/z calcd. C<sub>24</sub>H<sub>21</sub>FNaO<sub>7</sub> [M +  
344 Na]<sup>+</sup>: 463.1169, found 463.1195.

345 (1R, 2R, 3S)-1,2-propylacetal-3-*p*-methoxybenzoyl-zeilynone(A2)(65 mg, 92%) was synthesized  
346 by the same method as A1, except changed *p*-fluorobenzoic acid to *p*-methoxybenzoic acid. White  
347 powder;  $[\alpha]^{20}_D = 16.8$  (c = 0.3, CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, 298K, CDCl<sub>3</sub>): δ (ppm)= 7.95 (d, J = 7.2 Hz,  
348 2H, Ar-H), 7.80 (d, J = 8.9 Hz, 2H, Ar-H), 7.53 (t, J = 7.4 Hz, 1H, Ar-H), 7.37 (t, J = 7.8 Hz, 2H, Ar-H),  
349 7.05 (ddd, J = 10.2, 4.9, 1.8 Hz, 1H, H-4), 6.74 (d, J = 8.9 Hz, 2H, Ar-H), 6.37 (d, J = 10.2 Hz, 1H, H-5),  
350 5.94 (dd, J = 4.9, 1.2 Hz, 1H, H-3), 4.69 (d, J = 11.8 Hz, 1H, H-7a), 4.67 (t, J = 1.7 Hz, 1H, H-7b), 4.62 (d, J  
351 = 11.8 Hz, 1H, H-2), 3.81 (s, 3H, OMe), 1.48 (s, 3H, Me), 1.41 (s, 3H, Me); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  
352 δ (ppm)= 195.8 (s, C-1), 165.9 (s, C=O), 165.1 (s, C=O), 164.0 (s, C=C(OMe)), 142.0 (s, C-4), 133.6 (s,  
353 Ar-C), 132.1 (s, 2 × Ar-C), 132.1 (s, 2 × Ar-C), 130.7 (s, C-5), 129.9 (s, 2 × Ar-C), 129.3 (s, Ar-C), 128.6  
354 (s, 2 × Ar-C), 120.9 (s, Ar-C), 113.9 (s, 2 × Ar-C), 110.1 (s, CO<sub>2</sub>(Me)<sub>2</sub>), 80.2 (s, C-2), 77.8 (s, C-1), 65.8  
355 (s, C-3), 64.0 (s, C-7), 55.6 (s, OMe), 27.6 (s, Me), 26.6 (s, Me); HRMS (ESI): m/z calcd. C<sub>25</sub>H<sub>24</sub>NaO<sub>8</sub> [M  
356 + Na]<sup>+</sup>: 475.1369, found 475.1390.

357 (1R, 2R, 3S)-1,2-propylacetal-3-*p*-methylbenzoyl-zeilynone(A3)(55 mg, 85%) was synthesized  
358 by the same method as A1, except changed *p*-fluorobenzoic acid to *p*-methyl benzoic acid. White  
359 powder;  $[\alpha]^{20}_D = -25.9$  ( $c = 0.3$ ,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  (600 MHz, 298K,  $\text{CDCl}_3$ ):  $\delta$  (ppm) = 7.95 (dd,  $J = 8.3$ ,  
360 1.1 Hz, 2H, Ar-H), 7.73 (d,  $J = 8.2$  Hz, 2H, Ar-H), 7.52 (t,  $J = 7.5$  Hz, 1H, Ar-H), 7.36 (t,  $J = 7.8$  Hz, 2H,  
361 Ar-H), 7.07 (d,  $J = 7.9$  Hz, 2H, Ar-H), 7.05-7.03 (m, 1H, H-4), 6.37 (d,  $J = 10.2$  Hz, 1H, H-5), 5.95 (dd,  $J =$   
362 4.8, 1.2 Hz, 1H, H-3), 4.70 (d,  $J = 11.8$  Hz, 1H, H-7a), 4.68 (t,  $J = 1.7$  Hz, 1H, H-7b), 4.61 (d,  $J = 11.8$  Hz,  
363 1H, H-2), 2.35 (s, 3H, Me-Ph), 1.48 (s, 3H, Me), 1.41 (s, 3H, Me);  $^{13}\text{C NMR}$  (150 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) =  
364 195.8 (s, C-6), 165.8 (s, C=O), 165.4 (s, C=O), 144.7 (s, C-4), 141.8 (s, C=CMe), 133.5 (s, Ar-C), 130.7 (s, C-5),  
365 130.0 (s, 2 $\times$ Ar-C), 129.9 (s, 2 $\times$ Ar-C), 129.4 (s, 2 $\times$ Ar-C), 129.3 (s, Ar-C), 128.6 (s, 2 $\times$ Ar-C), 125.9 (s,  
366 Ar-C), 110.2 (s,  $\text{CO}_2(\text{Me})_2$ ), 80.2 (s, C-2), 77.8 (s, C-1), 65.9 (s, C-3), 64.0 (s, C-7), 27.6 (s, Me), 26.6 (s, Me),  
367 21.9 (s, Ar-Me); HRMS(ESI):  $m/z$  calcd.  $\text{C}_{22}\text{H}_{20}\text{NaO}_8[\text{M} + \text{Na}]^+$ : 435.1056, found 435.1080.

368 (1R, 2R, 3S)-1,2-propylacetal-3-(cyclohexanecarbonyl)-zeilynone(A4)(58 mg, 87%) was  
369 synthesized by the same method as A1, except changed *p*-fluorobenzoic acid to  
370 cyclohexanecarboxylic acid. White powder;  $[\alpha]^{20}_D = +22.5$  ( $c = 0.2$ ,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  (600 MHz, 298K,  
371  $\text{CDCl}_3$ ):  $\delta$  (ppm) = 7.99 (dd,  $J = 8.3$ , 1.2 Hz, 2H, Ar-H), 7.58 (t,  $J = 7.4$  Hz, 1H, Ar-H), 7.44 (t,  $J = 7.8$  Hz,  
372 2H, Ar-H), 6.82 (ddd,  $J = 10.2$ , 4.2, 1.4 Hz, 1H, H-4), 6.28 (dd,  $J = 10.2$ , 0.8 Hz, 1H, H-5), 5.69 (dd,  $J = 5.3$ ,  
373 2.0 Hz, 1H, H-3), 4.71 (d,  $J = 11.6$  Hz, 1H, H-7a), 4.52 (d,  $J = 11.6$  Hz, 1H, H-7b), 4.18 (dd,  $J = 3.2$ , 1.4 Hz,  
374 1H, H-2), 2.02-2.01 (m, 1H,  $\text{CHCO}(\text{CH}_2)_2$ ), 1.70-1.67 (m, 2H, H of cyclohexyl), 1.67-1.60 (m, 2H, H of  
375 cyclohexyl), 1.54 (s, 3H, Me), 1.45 (s, 3H, Me), 1.28-1.24 (m, 3H, H of cyclohexyl), 1.07-1.05 (m, 3H, H  
376 of cyclohexyl);  $^{13}\text{C NMR}$  (150 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) = 195.9 (s, C-1), 174.8 (s, C=O), 165.7 (s, C=O),  
377 141.8 (s, C-4), 133.6 (s, Ar-C), 130.7 (s, C-5), 129.9 (s, 2 $\times$ Ar-C), 129.4 (s, Ar-C), 128.7 (s, 2 $\times$ Ar-C),  
378 110.1 (s,  $\text{CO}_2(\text{Me})_2$ ), 80.0 (s, C-2), 77.9 (s, C-1), 64.9 (s, C-3), 64.0 (s, C-7), 42.8 (s, C of cyclohexyl), 29.0  
379 (s, C of cyclohexyl), 28.9 (s, C of cyclohexyl), 27.5 (s, Me), 26.5 (s, Me), 25.6 (s, C of cyclohexyl), 25.3 (s,  
380 C of cyclohexyl), 25.3 (s, C of cyclohexyl); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{24}\text{H}_{28}\text{NaO}_7[\text{M} + \text{Na}]^+$ : 451.1733,  
381 found 451.1731.

382 (1R, 2R, 3S)-1,2-propylacetal-3-(phenylpropanecarbonyl)-zeilynone(A5)(60 mg, 85%) was  
383 synthesized by the same method as A1, except changed *p*-fluorobenzoic acid to hydrocinnamic acid.  
384 White powder;  $[\alpha]^{20}_D = -13.1$  ( $c = 0.3$ ,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  (600 MHz, 298K,  $\text{CDCl}_3$ ):  $\delta$  (ppm) = 7.97 (dd,  $J =$   
385 8.3, 1.2 Hz, 2H, Ar-H), 7.57-7.52 (m, 1H, Ar-H), 7.40 (t,  $J = 7.8$  Hz, 2H, Ar-H), 7.24 (t,  $J = 7.3$  Hz, 2H,  
386 Ar-H), 7.21-7.18 (m, 1H, Ar-H), 7.02 (d,  $J = 7.1$  Hz, 2H, Ar-H), 6.82 (ddd,  $J = 10.2$ , 5.0, 1.8 Hz, 1H, H-4),  
387 6.30 (d,  $J = 10.3$  Hz, 1H, H-5), 5.68 (dd,  $J = 5.0$ , 1.4 Hz, 1H, H-3), 4.60 (d,  $J = 11.5$  Hz, 1H, H-7a), 4.51 (d,  
388  $J = 11.5$  Hz, 1H, H-7b), 4.34 (t,  $J = 1.8$  Hz, 1H, H-2), 2.80 (t,  $J = 7.7$  Hz, 2H,  $\text{CH}_2\text{CH}_2\text{-Ph}$ ), 2.42 (dt,  $J =$   
389 15.7, 7.8 Hz, 1H,  $\text{CH}_2\text{CH}_2\text{-Ph}$ ), 2.35-2.32 (m, 1H,  $\text{CH}_2\text{CH}_2\text{-Ph}$ ), 1.44 (s, 3H, Me), 1.36 (s, 3H, Me);  $^{13}\text{C}$   
390 NMR (150 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) = 196.0 (s, C-1), 171.7 (s, C=O), 166.1 (s, C=O), 142.9 (s, C-4), 142.9  
391 (s, Ar-C), 139.8 (s, Ar-C), 133.6 (s, 2 $\times$ Ar-C), 129.8 (s, Ar-C), 129.2 (s, 2 $\times$ Ar-C), 128.6 (s, 2 $\times$ Ar-C),  
392 128.6 (s, 2 $\times$ Ar-C), 128.3 (s, C-5), 126.5 (s, Ar-C), 109.9 (s,  $\text{CO}_2(\text{Me})_2$ ), 80.1 (s, C-2), 78.1 (s, C-1), 65.1 (s,  
393 C-3), 64.1 (s, C-7), 35.6 (s,  $\text{CH}_2$ ), 30.9 (s,  $\text{CH}_2$ ), 27.5 (s, Me), 26.5 (s, Me); HRMS (ESI):  $m/z$  calcd.  
394  $\text{C}_{26}\text{H}_{26}\text{NaO}_7[\text{M} + \text{Na}]^+$ : 473.1576, found 473.1604.

395 (1R, 2R, 3S)-1,2-propylacetal-3-(phenethylcarbonyl)-zeilynone(A6)(55 mg, 85%) was  
396 synthesized by the same method as A1, except changed *p*-fluorobenzoic acid to phenylacetic  
397 acid. White powder;  $[\alpha]^{20}_D = -22.5$  ( $c = 0.5$ ,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  (600 MHz, 298K,  $\text{CDCl}_3$ ):  $\delta$  (ppm) = 8.01  
398 (dd,  $J = 8.2$ , 1.1 Hz, 2H, Ar-H), 7.60 (t,  $J = 7.5$  Hz, 1H, Ar-H), 7.46 (t,  $J = 7.8$  Hz, 2H, Ar-H), 7.21-7.20  
399 (m, 2H, Ar-H), 7.08 (dd,  $J = 7.4$ , 1.7 Hz, 2H, Ar-H), 6.90 (ddd,  $J = 10.2$ , 5.0, 1.8 Hz, 1H, H-4), 6.33 (d,  $J$   
400 = 10.2 Hz, 1H, H-5), 5.70 (dd,  $J = 5.0$ , 1.6 Hz, 1H, H-3), 4.68 (d,  $J = 11.7$  Hz, 1H, H-7a), 4.47 (t,  $J = 1.8$



401 Hz, 1H, H-2), 4.44 (d,  $J = 11.7$  Hz, 1H, H-7b), 3.41 (dd,  $J = 37.7, 15.4$  Hz, 2H, CH<sub>2</sub>-Ph), 1.43 (s, 3H,  
402 Me), 1.35 (s, 3H, Me); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm)= 195.7 (s, C-6), 170.4 (s, C=O), 165.7 (s,  
403 C=O), 141.3 (s, C-4), 133.7 (s, Ar-C), 133.0 (s, Ar-C), 131.0 (s, C-5), 130.0 (s, 2  $\times$  Ar-C), 129.5 (s, Ar-C),  
404 129.3(s, 2  $\times$  Ar-C), 128.8 (s, 2  $\times$  Ar-C), 128.8 (s, 2  $\times$  Ar-C), 127.6 (s, Ar-C), 110.2 (s, CO<sub>2</sub>(Me)<sub>2</sub>), 80.0 (s,  
405 C-2), 77.5 (s, C-1), 65.7 (s, C-3), 63.7 (s, C-7), 40.8 (s, CH<sub>2</sub>(CO)Ar), 27.5 (s, Me), 26.5 (s, Me); HRMS  
406 (ESI): m/z calcd. C<sub>22</sub>H<sub>20</sub>NaO<sub>7</sub> [M + Na]<sup>+</sup>: 459.1420, found 459.1446.

### 407 3.2.11. synthesis of series B

408 Series B compounds were synthesized from Series A using the same method. To a solution of  
409 Series A in 1 m THF, added 1N dilute hydrochloric acid 1ml, and stirred for 1h. The mixture was  
410 concentrated to get the crude product. Crude product was purified by silica gel column  
411 chromatography (petroleum ether: ethyl acetate, 2:1) to give Series B.

412 (1R, 2R, 3S)-3-*p*-fluorobenzoyl-zeilynone(B1): White solid;  $[\alpha]^{20}_D = 18.0$  ( $c = 0.3$ , CHCl<sub>3</sub>); <sup>1</sup>H NMR  
413 (600 MHz, 298K, CDCl<sub>3</sub>):  $\delta$  (ppm)= 8.03-8.01 (m, 2H, Ar-H), 7.93-7.92 (m, 2H, Ar-H), 7.56 (t,  $J = 7.4$   
414 Hz, 1H, Ar-H), 7.41 (t,  $J = 7.8$  Hz, 2H, Ar-H), 7.08 (t,  $J = 8.6$  Hz, 2H, Ar-H), 6.95 (ddd,  $J = 10.2, 4.1, 1.2$   
415 Hz, 1H, H-4), 6.34 (d,  $J = 10.2$  Hz, 1H, H-5), 5.94 (m, 1H, H-3), 4.80 (d,  $J = 11.5$  Hz, 1H, H-7a), 4.59 (d,  
416  $J = 11.5$  Hz, 1H, H-7b), 4.37 (s, 1H, H-2), 4.10 (s, OH), 3.24 (s, OH); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>):  $\delta$   
417 (ppm)= 196.3 (s, C-1), 166.8 (d,  $J_{C-F} = 253.5$  Hz, C-F), 166.4 (s, C=O), 164.6 (s, C=O), 142.8 (s, C-4), 133.7  
418 (s, Ar-C), 132.6 (s, Ar-C), 132.6 (s, Ar-C), 129.9 (s, 2  $\times$  Ar-C), 129.2 (s, Ar-C), 128.8 (s, C-5), 128.6 (s, 2  
419  $\times$  Ar-C), 125.1 (s, Ar-C), 116.1 (s, Ar-C), 116.0 (s, Ar-C), 77.4 (s, C-2), 71.7 (s, C-1), 69.5 (s, C-3), 65.5  
420 (s, C-7); HRMS m/z calcd. C<sub>21</sub>H<sub>17</sub>FNaO<sub>7</sub> [M + Na]<sup>+</sup>: 423.0857, found 423.0856

421 (1R, 2R, 3S)-3-*p*-methoxybenzoyl-zeilynone(B2): White solid;  $[\alpha]^{20}_D = -22.9$  ( $c = 0.5$ , CHCl<sub>3</sub>);  
422 <sup>1</sup>H NMR (600 MHz, 298K, CDCl<sub>3</sub>):  $\delta$  (ppm)= 7.96 (d,  $J = 9.0$  Hz, 2H, Ar-H), 7.94 (dd,  $J = 8.3, 1.2$  Hz, 2H,  
423 Ar-H), 7.55 (t,  $J = 7.4$  Hz, 1H, Ar-H), 7.41 (dd,  $J = 8.1, 7.6$  Hz, 2H, Ar-H), 6.96 (ddd,  $J = 10.2, 4.2, 1.5$   
424 Hz, 1H, H-4), 6.89 (d,  $J = 9.0$  Hz, 2H, Ar-H), 6.33 (dd,  $J = 10.2, 0.9$  Hz, 1H, H-5), 5.95-5.90 (m, 1H,  
425 H-3), 4.84 (d,  $J = 11.5$  Hz, 1H, H-7a), 4.59 (d,  $J = 11.5$  Hz, 1H, H-7b), 4.36 (dd,  $J = 3.3, 1.5$  Hz, 1H, H-2),  
426 4.11 (s, OH), 3.85 (s, 3H, OMe), 3.18 (s, OH); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm)= 196.6 (s, C-6),  
427 166.3 (s, C=O), 165.2 (s, C=O), 164.1 (s, C=C(OMe)), 143.1 (s, C-4), 139.9 (s, Ar-C), 133.6 (s, Ar-C),  
428 132.1 (s, 2  $\times$  Ar-C), 129.9 (s, 2  $\times$  Ar-C), 129.3 (s, Ar-C), 128.6 (s, 2  $\times$  Ar-C), 128.6 (s, C-5), 121.1 (s, Ar-C),  
429 114.1 (s, 2  $\times$  Ar-C), 77.4 (s, C-2), 71.8 (s, C-1), 69.0 (s, C-3), 65.7 (s, C-7), 55.7 (s, OMe); HRMS (ESI):  
430 m/z calcd. C<sub>22</sub>H<sub>20</sub>NaO<sub>8</sub> [M + Na]<sup>+</sup>: 435.1056, found 435.1080

431 (1R, 2R, 3S)-3-*p*-methylbenzoyl-zeilynone(B3): White solid;  $[\alpha]^{20}_D = -14.9$  ( $c = 0.2$ , CHCl<sub>3</sub>);  
432 <sup>1</sup>H NMR (600 MHz, 298K, CDCl<sub>3</sub>):  $\delta$  (ppm)= 7.94 (d,  $J = 7.5$  Hz, 2H, Ar-H), 7.90 (d,  $J = 8.1$  Hz, 2H,  
433 Ar-H), 7.55 (t,  $J = 7.4$  Hz, 1H, Ar-H), 7.41 (t,  $J = 7.7$  Hz, 2H, Ar-H), 7.21 (d,  $J = 8.0$  Hz, 2H, Ar-H), 6.96  
434 (dd,  $J = 10.1, 3.9$  Hz, 1H, H-4), 6.33 (d,  $J = 10.2$  Hz, 1H, H-5), 5.94 (t,  $J = 3.5$  Hz, 1H, H-3), 4.84 (d,  $J =$   
435 11.5 Hz, 1H, H-7a), 4.59 (d,  $J = 11.5$  Hz, 1H, H-7b), 4.37 (d,  $J = 2.2$  Hz, 1H, H-2), 2.39 (s, 3H, Me-Ph);  
436 <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm)= 196.5 (s, C-6), 166.3 (s, C=O), 165.6 (s, C=O), 144.9 (s, C-4),  
437 143.0 (s, C=CMe), 133.6 (s, Ar-C), 130.0 (s, 2  $\times$  Ar-C), 129.9 (s, 2  $\times$  Ar-C), 129.5 (s, 2  $\times$  Ar-C), 129.3 (s,  
438 Ar-C), 128.7 (s, C-5), 128.6 (s, 2  $\times$  Ar-C), 126.1 (s, Ar-C), 77.4 (s, C-2), 71.8 (s, C-1), 69.2 (s, C-3), 65.6 (s,  
439 C-7), 21.9 (s, Ar-Me); HRMS (ESI): m/z calcd. C<sub>22</sub>H<sub>20</sub>NaO<sub>7</sub> [M + Na]<sup>+</sup>: 419.1107, found 419.113.

440 (1R, 2R, 3S)-3-(cyclohexanecarbonyl)-zeylenone(B4): White solid;  $[\alpha]^{20}_D = +33.8$  (c = 0.2, CHCl<sub>3</sub>);  
441 <sup>1</sup>H-NMR (600 MHz, 298K, CDCl<sub>3</sub>):  $\delta$  (ppm) = 7.99 (dd, J = 8.3, 1.2 Hz, 2H, Ar-H), 7.58 (t, J = 7.4 Hz,  
442 1H, Ar-H), 7.44 (t, J = 7.8 Hz, 2H, Ar-H), 6.82 (ddd, J = 10.2, 4.2, 1.4 Hz, 1H, H-4), 6.28 (dd, J = 10.2,  
443 0.8 Hz, 1H, H-5), 5.69 (dd, J = 5.3, 2.0 Hz, 1H, H-3), 4.71 (d, J = 11.6 Hz, 1H, H-7a), 4.52 (d, J = 11.6  
444 Hz, 1H, H-7b), 4.18 (dd, J = 3.2, 1.4 Hz, 1H, H-2), 4.05 (br s, OH), 3.07 (br s, OH), 2.39-2.30 (m, 1H,  
445 CHCO(CH<sub>2</sub>)<sub>2</sub>), 1.98-1.84 (m, 2H, H of cyclohexyl), 1.77-1.63 (m, 3H, H of cyclohexyl), 1.44 (qd, J =  
446 13.0, 3.5 Hz, 2H, H of cyclohexyl), 1.24 (ddd, J = 24.6, 12.2, 5.8 Hz, 3H, H of cyclohexyl); <sup>13</sup>CNMR  
447 (150 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) = 196.5 (s, C-1), 174.9 (s, C=O), 166.3 (s, C=O), 143.0 (s, C-4), 133.7 (s,  
448 Ar-C), 129.9 (s, C-5), 129.3 (s, 2×Ar-C), 128.7 (s, Ar-C), 128.4 (s, 2×Ar-C), 77.3 (s, C-2), 71.8 (s, C-1),  
449 68.4 (s, C-3), 65.7 (s, C-7), 42.1 (s, C of cyclohexyl), 29.1 (s, C of cyclohexyl), 29.1 (s, C of cyclohexyl),  
450 25.7 (s, C of cyclohexyl), 25.4 (s, 2×C of cyclohexyl); HRMS (ESI): m/z calcd. C<sub>21</sub>H<sub>24</sub>NaO<sub>7</sub> [M + Na]<sup>+</sup>:  
451 411.1420, found 411.1441.

452 (1R, 2R, 3S)-3-(phenylpropanecarbonyl)-zeylenone(B5): White solid;  $[\alpha]^{20}_D = +20.6$  (c = 0.3,  
453 CHCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, 298K, CDCl<sub>3</sub>):  $\delta$  (ppm) = 8.03-7.95 (m, 2H, Ar-H), 7.58 (t, J = 7.4 Hz, 1H,  
454 Ar-H), 7.44 (t, J = 7.7 Hz, 2H, Ar-H), 7.28 (t, J = 7.5 Hz, 2H, Ar-H), 7.20 (t, J = 7.4 Hz, 1H, Ar-H), 7.16  
455 (d, J = 7.2 Hz, 2H, Ar-H), 6.71 (dd, J = 10.2, 3.9 Hz, 1H, H-4), 6.23 (d, J = 10.2 Hz, 1H, H-5), 5.68 (dd, J  
456 = 5.2, 2.4 Hz, 1H, H-3), 4.61 (d, J = 11.5 Hz, 1H, H-7a), 4.45 (d, J = 11.5 Hz, 1H, H-7b), 4.08 (d, J = 3.6  
457 Hz, 1H, H-2), 4.08 (s, OH), 3.18 (s, OH), 2.95 (dd, J = 11.7, 4.5 Hz, 2H, CH<sub>2</sub>CH<sub>2</sub>-Ph), 2.69 (td, J = 7.7,  
458 3.6 Hz, 2H, CH<sub>2</sub>CH<sub>2</sub>-Ph); <sup>13</sup>CNMR (150 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) = 196.2 (s, C-1), 171.9 (s, C=O), 166.3 (s,  
459 C=O), 143.0 (s, C-4), 139.9 (s, Ar-C), 133.7 (s, Ar-C), 129.9 (s, 2×Ar-C), 129.3 (s, Ar-C), 128.7 (s,  
460 2×Ar-C), 128.7 (s, 2×Ar-C), 128.4 (s, 2×Ar-C), 128.4 (s, C-5), 126.7 (s, Ar-C), 77.2 (s, C-2), 71.7 (s,  
461 C-1), 69.0 (s, C-3), 65.2 (s, C-7), 35.8 (s, CH<sub>2</sub>), 31.0 (s, CH<sub>2</sub>); HRMS (ESI): m/z calcd. C<sub>23</sub>H<sub>22</sub>NaO<sub>7</sub> [M +  
462 Na]<sup>+</sup>: 433.1263, found 433.1275.

463 (1R, 2R, 3S)-3-(phenethylcarbonyl)-zeylenone(B6): White solid;  $[\alpha]^{20}_D = +15.0$  (c = 0.5, CHCl<sub>3</sub>);  
464 <sup>1</sup>H-NMR (600 MHz, 298K, CDCl<sub>3</sub>):  $\delta$  (ppm) = 7.98 (d, J = 7.1 Hz, 1H, Ar-H), 7.59 (t, J = 7.5 Hz, 1H,  
465 Ar-H), 7.45 (dd, J = 8.1, 7.6 Hz, 1H, Ar-H), 7.35-7.28 (m, 1H, Ar-H), 7.28-7.22 (m, 3H, Ar-H), 6.79  
466 (ddd, J = 10.2, 4.1, 1.4 Hz, 1H, H-4), 6.26 (dd, J = 10.2, 0.9 Hz, 1H, H-5), 5.72-5.67 (m, 1H, H-3), 4.61 (d,  
467 J = 11.6 Hz, 1H, H-7a), 4.35 (d, J = 11.6 Hz, 1H, H-7b), 4.14-4.09 (m, 1H, H-2), 4.03 (s, 1H, OH),  
468 3.73-3.63 (m, 2H, CH<sub>2</sub>-Ph), 3.10 (s, 1H, OH). <sup>13</sup>CNMR (150 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) = 196.3 (s, C-6), 170.5  
469 (s, C=O), 166.2 (s, C=O), 142.5 (s, C-4), 133.7 (s, Ar-C), 133.1 (s, Ar-C), 129.9 (s, 2×Ar-C), 129.4 (s,  
470 2×Ar-C), 129.3 (s, Ar-C), 129.0 (s, 2×Ar-C), 128.7 (s, 2×Ar-C), 128.6 (s, C-5), 127.7 (s, Ar-C), 77.3 (s,  
471 C-2), 71.7 (s, C-1), 69.1 (s, C-3), 65.4 (s, C-7), 41.3 (s, CH<sub>2</sub>(CO)Ar).

### 472 3.2.12. synthesis of series C

473 C1 and C2: (+)-Zeylenone (40 mg, 0.11 mmol) was dissolved in 2 ml DCM, then triethylamine  
474 (15  $\mu$ l, 0.1 mmol), DMAP (1.5 mg, 0.1 mmol), acetyl chloride (15.5  $\mu$ l, 0.22 mmol) were added  
475 successively. After stirred for 2 h at RT, the reaction was quenched with saturated sodium  
476 bicarbonate solution, and extraction with DCM, washed with saturated sodium chloride, dried  
477 (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Crude product was purified by silica gel  
478 column chromatography (petroleum ether: ethyl acetate, 6:1) to give C1 (11 mg, 25%), and  
479 (petroleum ether: ethyl acetate, 4:1) to give C2 (27 mg, 71%).

480 (1R, 2R, 3S)-2-acetyl-zeylenone(C1): White solid;  $[\alpha]^{20}_D = +33.5$  (c = 0.3, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (500  
481 MHz, CDCl<sub>3</sub>)  $\delta$  8.01 (ddd, J = 17.5, 8.2, 1.1 Hz, 4H), 7.59 – 7.55 (m, 2H), 7.44 (t, J = 7.6 Hz, 4H), 7.02



482 (ddd,  $J = 10.3, 3.6, 0.9$  Hz, 1H), 6.38 (dd,  $J = 10.3, 1.1$  Hz, 1H), 5.95 – 5.93 (m, 1H), 5.82 (dd,  $J = 4.4, 0.8$   
483 Hz, 1H), 4.80 (d,  $J = 11.4$  Hz, 1H), 4.71 (d,  $J = 11.4$  Hz, 1H), 3.76 (s, 1H, OH), 2.09 (s, 3H);  $^{13}\text{C}$ NMR (125  
484 MHz,  $\text{CDCl}_3$ )  $\delta$  195.00 (s), 169.52 (s), 166.19 (s), 165.39 (s), 143.27 (s), 134.09 (s), 133.62 (s), 130.05 (s),  
485 129.95 (s), 129.33 (s), 129.08 (s), 128.91 (s), 128.69 (s), 76.27 (s), 71.71 (s), 68.77 (s), 65.20 (s), 20.80(s);  
486 HRMS (ESI):  $m/z$  calcd.  $\text{C}_{24}\text{H}_{20}\text{NaO}_8$   $[\text{M} + \text{Na}]^+$ : 447.1056, found 447.1056

487 (1R, 2R, 3S)-1,2-diacetyl-zeaylenone(C2): White solid;  $[\alpha]^{20}_D = +12.05$  ( $c = 0.1, \text{CHCl}_3$ );  $^1\text{H}$ NMR  
488 (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.00 (ddd,  $J = 13.5, 8.3, 1.1$  Hz, 4H), 7.57 (ddd,  $J = 9.7, 6.8, 2.4$  Hz, 2H), 7.45 (ddd,  $J$   
489  $= 7.7, 3.9, 2.3$  Hz, 4H), 6.87 (dd,  $J = 10.5, 2.1$  Hz, 1H), 6.32 (dd,  $J = 10.5, 2.3$  Hz, 1H), 6.18 (d,  $J = 8.3$  Hz,  
490 1H), 5.92 (d,  $J = 8.3$  Hz, 1H), 4.89 (d,  $J = 10.9$  Hz, 1H), 4.64 (d,  $J = 11.0$  Hz, 1H), 2.18 (s, 3H), 2.01 (s, 3H);  
491  $^{13}\text{C}$ NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  190.19 (s), 169.61 (s), 166.19 (s), 165.99 (s), 165.65 (s), 143.87 (s), 133.98  
492 (s), 133.60 (s), 130.09 (s), 129.97 (s), 129.41 (s), 129.35 (s), 128.99 (s), 128.88 (s), 128.69 (s), 80.82 (s), 71.39  
493 (s), 70.82 (s), 61.73 (s), 20.81 (s), 20.72 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{25}\text{H}_{22}\text{NaO}_9$   $[\text{M} + \text{Na}]^+$ : 489.1162,  
494 found 489.1158.

495 C3 and C4 were synthesized synthesized by the same method as C1 and C2, except changed  
496 acetyl chloride to propionyl chloride.

497 (1R, 2R, 3S)-2-propionyl-zeaylenone(C3) (10 mg, 24%) White solid;  $[\alpha]^{20}_D = +16.3$  ( $c = 0.1, \text{CHCl}_3$ );  
498  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.00 (d,  $J = 7.3$  Hz, 2H), 7.96 (d,  $J = 7.3$  Hz, 2H), 7.56 (dd,  $J = 17.3, 7.5$  Hz,  
499 2H), 7.41 (td,  $J = 7.8, 3.7$  Hz, 4H), 7.00 (dd,  $J = 10.2, 3.7$  Hz, 1H), 6.37 (d,  $J = 10.2$  Hz, 1H), 5.90 (t,  $J = 3.9$   
500 Hz, 1H), 5.81 (d,  $J = 4.2$  Hz, 1H), 4.78 (d,  $J = 11.4$  Hz, 1H), 4.67 (d,  $J = 11.4$  Hz, 1H), 3.59 (s, 1H, OH),  
501 2.34 (dd,  $J = 7.4, 6.4$  Hz, 2H), 1.08 (t,  $J = 7.5$  Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{CDCl}_3$ )  $\delta$  195.12 (s), 172.93 (s),  
502 166.14 (s), 165.30 (s), 143.08 (s), 134.04 (s), 133.57 (s), 130.01 (s), 129.89 (s), 129.06 (s), 128.85 (s), 128.65  
503 (s), 76.31 (s), 71.45 (s), 68.66 (s), 65.40 (s), 27.52 (s), 9.14 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{24}\text{H}_{22}\text{NaO}_8$   $[\text{M} +$   
504  $\text{Na}]^+$ : 461.1212, found 461.1156.

505 (1R, 2R, 3S)-1,2-dipropionyl-zeaylenone(C4) (30 mg, 71%): White solid;  $[\alpha]^{20}_D = -18.8$  ( $c = 0.1,$   
506  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.99 (ddd,  $J = 15.8, 8.3, 1.2$  Hz, 4H), 7.58 – 7.56 (m, 2H), 7.44  
507 (ddd,  $J = 9.4, 5.9, 2.0$  Hz, 4H), 6.88 (dd,  $J = 10.5, 2.0$  Hz, 1H), 6.33 (dd,  $J = 10.5, 2.3$  Hz, 1H), 6.19 (dd,  $J =$   
508  $8.3, 2.1$  Hz, 1H), 5.95 (d,  $J = 8.4$  Hz, 1H), 4.88 (d,  $J = 10.8$  Hz, 1H), 4.60 (d,  $J = 10.9$  Hz, 1H), 2.46 (q,  $J =$   
509  $7.5$  Hz, 2H), 2.30 – 2.25 (m, 2H), 1.17 (t,  $J = 7.5$  Hz, 3H), 0.96 (t,  $J = 7.5$  Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz,  
510  $\text{CDCl}_3$ )  $\delta$  190.31 (s), 173.10 (s), 173.06 (s), 165.94 (s), 165.58 (s), 143.97 (s), 133.97 (s), 133.53 (s), 130.04  
511 (s), 129.91 (s), 129.38 (s), 129.06 (s), 128.95 (s), 128.63 (s), 80.47 (s), 71.12 (s), 70.83 (s), 61.96 (s), 27.43 (s),  
512 27.32 (s), 9.12 (s), 9.07 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{27}\text{H}_{26}\text{NaO}_9$   $[\text{M} + \text{Na}]^+$ : 517.1475, found 517.1472.

513 C5 and C6 were synthesized synthesized by the same method as C1 and C2, except changed  
514 acetyl chloride to benzoyl chloride.

515 (1R, 2R, 3S)-2-benzoyl-zeaylenone(C5) (12 mg, 20%) White solid;  $[\alpha]^{20}_D = -24.5$  ( $c = 0.3, \text{CHCl}_3$ );  
516  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.03 (d,  $J = 7.3$  Hz, 2H), 7.98 (d,  $J = 7.5$  Hz, 4H), 7.60 – 7.56 (m, 3H), 7.45 –  
517 7.40 (m, 6H), 7.09 (ddd,  $J = 10.3, 3.4, 1.8$  Hz, 1H), 6.49 (d,  $J = 10.3$  Hz, 1H), 6.05 (d,  $J = 3.7$  Hz, 2H), 4.93  
518 (d,  $J = 11.5$  Hz, 1H), 4.76 (d,  $J = 11.5$  Hz, 1H), 3.79 (s, 1H, OH);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  195.65 (s),  
519 166.26 (s), 165.22 (s), 165.06 (s), 142.77 (s), 134.03 (s), 133.83 (s), 133.54 (s), 130.10 (s), 130.02 (s), 129.90  
520 (s), 129.24 (s), 129.17 (s), 128.97 (s), 128.84 (s), 128.70 (s), 128.61 (s), 76.54 (s), 72.36 (s), 68.41 (s), 66.13  
521 (s); HRMS (ESI):  $m/z$  calcd.  $\text{C}_{28}\text{H}_{22}\text{NaO}_8$   $[\text{M} + \text{Na}]^+$ : 509.1212, found 509.1208.

522 (1R, 2R, 3S)-1,2-dibenzoyl-zeulenone(C6) (33 mg,64%) White solid;  $[\alpha]^{20}_D = 10.9$  (c = 0.1, CHCl<sub>3</sub>);  
523 <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.09 (dd, J = 8.3, 1.2 Hz, 2H), 7.97 (dd, J = 8.3, 1.2 Hz, 2H), 7.89 (ddd, J =  
524 15.8, 8.3, 1.2 Hz, 4H), 7.64 (dd, J = 10.6, 4.3 Hz, 1H), 7.53 – 7.52 (m, 5H), 7.37 (dt, J = 24.6, 7.9 Hz, 4H),  
525 7.29 (d, J = 8.1 Hz, 2H), 6.99 (dd, J = 10.4, 2.3 Hz, 1H), 6.46 (dd, J = 10.2, 7.9 Hz, 2H), 6.32 (d, J = 8.1 Hz,  
526 1H), 5.05 (d, J = 11.0 Hz, 1H), 4.83 (d, J = 11.0 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  190.26 (s), 165.97  
527 (s), 165.56 (s), 165.20 (s), 165.12 (s), 144.27 (s), 134.27 (s), 133.80 (s), 133.39 (s), 130.34 (s), 129.99 (d, J =  
528 17.8 Hz), 129.55 (s), 128.96 (s), 128.92 (s), 128.71 (s), 128.65 (s), 128.62 (s), 128.52 (s), 128.44 (s), 80.62 (s),  
529 72.10 (s), 70.94 (s), 62.98 (s); HRMS (ESI): m/z calcd. C<sub>35</sub>H<sub>26</sub>NaO<sub>9</sub> [M + Na]<sup>+</sup>: 613.1475, found 613.1470.

530 C7 and C8 were synthesized synthesized by the same method as C1 and C2, except changed  
531 acetyl chloride to cinnamoyl chloride.

532 (1R, 2R, 3S)-2-cinnamoyl-zeulenone(C7) (15 mg, 18%) White solid;  $[\alpha]^{20}_D = -25.8$  (c = 0.1, CHCl<sub>3</sub>);  
533 <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.03 (dd, J = 18.5, 7.3 Hz, 5H), 7.71 (d, J = 16.0 Hz, 1H), 7.60 – 7.54 (m,  
534 2H), 7.50 – 7.49 (m, 2H), 7.42 (m, 8H), 7.07 (dd, J = 10.3, 3.7 Hz, 1H), 6.45 – 6.42 (d, J = 10.2 Hz, 1H),  
535 6.42 (d, J = 16.0 Hz, 1H), 6.04 (dd, J = 5.7, 2.2 Hz, 1H), 5.96 (d, J = 4.4 Hz, 1H), 4.87 (d, J = 11.4 Hz, 1H),  
536 4.76 (d, J = 11.4 Hz, 1H), 3.78 (s, 1H, OH); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  195.07 (s), 166.11 (s), 165.25  
537 (d, J = 12.5 Hz), 146.88 (s), 143.08 (s), 133.90 (d, J = 11.6 Hz), 133.40 (s), 130.77 (s), 129.89 (s), 129.80 (s),  
538 128.94 (s), 128.93 (s), 128.70 (s), 128.70 (s), 128.48 (s), 128.34 (s), 128.14 (s), 116.43 (s), 76.24 (s), 71.80 (s),  
539 68.58 (s), 65.50 (s); HRMS (ESI): m/z calcd. C<sub>30</sub>H<sub>42</sub>NaO<sub>8</sub> [M + Na]<sup>+</sup>: 535.1369, found 535.1367.

540 (1R, 2R, 3S)-1,2-dicinnamoyl-zeulenone(C8) (37 mg, 68%) White solid;  $[\alpha]^{20}_D = -37.9$  (c = 0.3,  
541 CHCl<sub>3</sub>); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 – 8.01 (m, 4H), 7.83 (d, J = 16.0 Hz, 1H), 7.65 (d, J = 16.0 Hz,  
542 1H), 7.60 – 7.58 (m, 3H), 7.55 (d, J = 7.4 Hz, 1H), 7.46 – 7.41(m, 10H), 7.33 (t, J = 7.3 Hz, 2H), 6.97 (dd, J  
543 = 10.5, 2.1 Hz, 1H), 6.58 (d, J = 16.0 Hz, 1H), 6.44 – 6.40 (m, 2H), 6.39 (d, J = 15.9 Hz, 2H), 6.18 (d, J = 8.3  
544 Hz, 1H), 5.03 (d, J = 11.0 Hz, 1H), 4.79 (d, J = 11.0 Hz, 1H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  190.31 (s),  
545 165.90 (s), 165.45 (s), 165.40 (s), 165.35 (s), 147.89 (s), 146.93 (s), 143.91 (s), 133.82 (s), 133.81 (s), 133.68  
546 (s), 133.27 (s), 131.07 (s), 130.76 (s), 129.94 (s), 129.86 (s), 129.35 (s), 129.05 (s), 128.85 (s), 128.61 (s),  
547 128.53 (s), 128.43 (s), 128.32 (s), 116.22 (s), 115.77 (s), 80.40 (s), 71.47 (s), 70.86 (s), 62.56 (s); HRMS  
548 (ESI): m/z calcd. C<sub>39</sub>H<sub>22</sub>NaO<sub>9</sub> [M + Na]<sup>+</sup>: 665.1788, found 665.1795.

### 549 3.3. Antitumor activity assays

#### 550 Cell Lines and Cell Culture

551 B16 melanoma cells, human hepatocellular carcinoma HepG2 cells, and human neuroblastoma  
552 SH-SY5Y were all obtained from the Chinese Academy of Medical Sciences Basic Medicine Cell  
553 Center (Beijing, China). B16 and SH-SY5Y cells were maintained in RPMI-1640 media containing  
554 10% FBS and 1% penicillin/streptomycin in a 37 °C humidified incubator with 5% CO<sub>2</sub>. HepG2 cells  
555 were cultured in DMEM media under the same conditions.

#### 556 Cell Viability Assay

557 Cell viability assay was determined using Cell Counting Kit-8 (CCK8) (Dojindo) according to  
558 manufacturer's protocol. Briefly, cells cultured in 96-well plates at a density of 4.5 × 10<sup>3</sup> cells/well  
559 were treated with various concentrations of test compound for 24 h. Then, 10 $\mu$ L CCK8 reagent was  
560 added to the media and allowed to incubate for another 2.5 h at 37 °C in an atmosphere of 5% CO<sub>2</sub>.

561 Cell viability was quantified by reading the plates at an absorbance of 450 nm using a microplate  
562 reader. Three independent experiments were carried out.

### 563 3. Conclusion

564 The total synthesis of (+) - zeylenone was completed in 13 steps with quinic acid as starting  
565 material in 8.8% overall yield. The highlight of the route was the control of the three carbon's  
566 chirality by clever use of single step dihydroxylation under the direction of the key C-3 chirality. The  
567 yield of each step is excellent, and the gram scale preparation can be achieved.

568 In order to investigate the influence of absolute configuration and hydroxyls at position C-1/2/3  
569 on the antitumor activity, zeylenone derivatives were designed and synthesized. Their antitumor  
570 activity was evaluated against three human cancer cell lines. Structure-activity relationship  
571 suggested that both two absolute configurations exhibited good activity, and (-)-zeylenone showed a  
572 little better efficacy. Besides, hydroxyls at C-1/2 position were crucial for the activity and  
573 esterification of large groups at C-1 hydroxyl made the activity disappeared. Proper ester group of  
574 hydroxyl at C-3 position could increase the efficiency. **B1** showed the highest IC<sub>50</sub> value to three cell  
575 lines, which was worthy to make further study. This article makes the structure-activity relationship  
576 clear and helps to find more potent antitumor agents.

577

#### 578 Author Contributions:

579 Xu Xudong is the teacher who provided financial support for this project. Tian Yu helped to  
580 analysis and write the paper. Ma Guoxu helped to isolate the (-)-zeylenone from plants. Yang  
581 Shuxian, Xu Chengfang, Cao Li, Lin Jiahao helps to finish the biological activity assay.

#### 582 Acknowledgments:

583 We thank analysis and testing center of The Institute of Medicinal Plant Development (IMPLAD) for NMR,  
584 LC-MS and IR analysis.

585 **Conflicts of Interest:** The authors declare no conflict of interest.

#### 586 References

- 587 1. Kinghorn, A. D., Review of Anticancer Agents from Natural Products Anticancer Agents from Natural  
588 Products, 2nd Edition. . *Journal of Natural Products* **2015**, 78, (9), 2315-2315.
- 589 2. Yong-Hong, L.; Li-Zhen, X.; Shi-Lin, Y.; Jie, D.; Yong-Su, Z.; Min, Z.; Nan-Jun, S., Three cyclohexene  
590 oxides from *Uvaria grandiflora*. *Phytochemistry* **1997**, 45, (4), 729-732.
- 591 3. Zhang, L.; Jin, J.; Zhang, L.; Hu, R.; Gao, L.; Huo, X.; Liu, D.; Ma, X.; Wang, C.; Han, J.; Li, L.; Sun, X.;  
592 Cao, L., Quantitative analysis of differential protein expression in cervical carcinoma cells after  
593 zeylenone treatment by stable isotope labeling with amino acids in cell culture. *Journal of proteomics*  
594 **2015**, 126, 279-87.
- 595 4. Huo, X.; Liao, Y.; Tian, Y.; Gao, L.; Cao, L., Zeylenone promotes apoptosis in chronic myelogenous  
596 leukemia-derived K562 cells by a mechanism involving Jak2 and Src kinase. *RSC Advances* **2016**, 6,  
597 (115), 114096-114108.
- 598 5. Zhang, L.; Huo, X.; Liao, Y.; Yang, F.; Gao, L.; Cao, L., Zeylenone, a naturally occurring cyclohexene  
599 oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR  
600 and MAPK/ERK pathways. *Scientific reports* **2017**, 7, (1), 1669.

- 601 6. Zeng, S.; Zhu, B.; Zeng, J.; Wu, W.; Jiang, C., Zeylenone represses the progress of human prostate  
602 cancer by downregulating the Wnt/betacatenin pathway. *Molecular medicine reports* **2018**, 18, (6),  
603 5572-5578.
- 604 7. Yang, S.; Liao, Y.; Li, L.; Xu, X.; Cao, L., Zeylenone Induces Mitochondrial Apoptosis and Inhibits  
605 Migration and Invasion in Gastric Cancer. *Molecules* **2018**, 23, (9).
- 606 8. Hiroya, K.; Kurihara, Y.; Ogasawara, K., Asymmetrization of meso 1,4-Enediol Ethers by Isomerization  
607 with a Chiral binap-RhI Catalyst. *Angewandte Chemie International Edition in English* **1995**, 34, (20),  
608 2287-2289.
- 609 9. Hiroya, K.; Ogasawara, K., The first enantiocontrolled synthesis of naturally occurring  
610 polyoxygenated cyclohexenylmethanol dibenzoates (-)-zeylenol, (-)-uvarigranol G, (-)-tonkinenin A  
611 and (+)-pipoxide. *Chemical Communications* **1999**, (21), 2197-2198.
- 612 10. Liu, A.; Liu, Z. Z.; Zou, Z. M.; Chen, S. Z.; Xu, L. Z.; Yang, S. L., Synthesis of (+)-zeylenone from  
613 shikimic acid. *Tetrahedron* **2004**, 60, (16), 3689-3694.
- 614 11. Zhang, Y.; Liu, A.; Ye, Z. G.; Lin, J.; Xu, L. Z.; Yang, S. L., New Approach to the Total Synthesis of  
615 (-)-Zeylenone from Shikimic Acid. *Chemical & Pharmaceutical Bulletin* **2006**, 54, (10), 1459-1461.
- 616 12. Palframan, M. J.; Kociok-Kohn, G.; Lewis, S. E., Photooxygenation of a microbial arene oxidation  
617 product and regioselective Kornblum-DeLaMare rearrangement: total synthesis of zeylenols and  
618 zeylenones. *Chemistry* **2012**, 18, (15), 4766-74.
- 619 13. Vinaykumar, A.; Muniraju, C.; Rao, B. V., Stereoselective total synthesis of (-)-zeylenol, a key  
620 intermediate for the synthesis of (+)-pipoxide, (-)-uvarigranol G and (-)-tonkinenin A. *Tetrahedron*  
621 *Letters* **2017**, 58, (11), 1075-1077.
- 622 14. Arthurs, C. L.; Wind, N. S.; Whitehead, R. C.; Stratford, I. J., Analogues of  
623 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) with anti-tumor  
624 properties. *Bioorganic & medicinal chemistry letters* **2007**, 17, (2), 553-7.
- 625 15. Arthurs, C. L.; Lingley, K. F.; Piacenti, M.; Stratford, I. J.; Tatic, T.; Whitehead, R. C.; Wind, N. S.,  
626 (-)-Quinic acid: a versatile precursor for the synthesis of analogues of  
627 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) which possess  
628 anti-tumour properties. *Tetrahedron Letters* **2008**, 49, (15), 2410-2413.
- 629 16. Schuster, H.; Martinez, R.; Bruss, H.; Antonchick, A. P.; Kaiser, M.; Schurmann, M.; Waldmann, H.,  
630 Synthesis of the B-seco limonoid scaffold. *Chem Commun (Camb)* **2011**, 47, (23), 6545-7.
- 631 17. Barros, M. T.; Maycock, C. D.; Ventura, M. R., Approaches to the synthesis of (+)- and (-)-epibatidine†.  
632 *Journal of the Chemical Society, Perkin Transactions 1* **2001**, (2), 166-173.
- 633 18. Li, M.; Li, Y.; Ludwik, K. A.; Sandusky, Z. M.; Lannigan, D. A.; O'Doherty, G. A., Stereoselective  
634 Synthesis and Evaluation of C6"-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of  
635 RSK1/2. *Organic letters* **2017**, 19, (9), 2410-2413.

636 **Sample Availability:** Samples of the compounds (+)-Zeylenone, (-)-Zeylenone, A1-A6, B1-B6, C1-C8 are  
637 available from the authors.

638